SCHEMBL6489883

SCHEMBL6489883

Cc1ccc(C(=O)O)c(-c2ccc(Cl)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
HDAC7 Q8WUI4 1/20 0.51
AURKA O14965 1/20 0.50
TPX2 Q9ULW0 1/20 0.50
ANO1 Q5XXA6 1/20 0.48
DHODH Q02127 3/20 0.48
METAP2 P50579 1/20 0.48
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48
PRKAB2 O43741 1/20 0.48
PRKAG1 P54619 1/20 0.48
PRKAA2 P54646 1/20 0.48
PRKAA1 Q13131 1/20 0.48
PRKAG3 Q9UGI9 1/20 0.48
PRKAG2 Q9UGJ0 1/20 0.48
PRKAB1 Q9Y478 1/20 0.48
AKR1C2 P52895 1/20 0.47
AKR1C1 Q04828 1/20 0.47
TP53 P04637 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492374 0.90 DHODH (0.55) NPC1RAB9AHDAC7AURKATPX2
SCHEMBL6498971 0.89 HDAC7 (0.57) NPC1RAB9AHDAC7PRKAB2PRKAG1
SCHEMBL6499129 0.86 HSD17B10 (0.51) NPC1RAB9AAURKATPX2ANO1
SCHEMBL809394 0.85 ALDH1A1 (0.59) NPC1RAB9AAURKATPX2ANO1
SCHEMBL11154359 0.84 ALDH1A1 (0.55) NPC1RAB9AHDAC7SMN1; SMN2ALDH1A1
SCHEMBL9683573 0.84 HSD17B10 (0.58) HDAC7DHODHPRKAB2PRKAG1PRKAA2
SCHEMBL3229733 0.84 HDAC7 (0.70) HDAC7AKR1C2AKR1C1ALDH1A1TSHR
SCHEMBL6549614 0.83 PRKAB2 (0.50) HDAC7DHODHPRKAB2PRKAG1PRKAA2
SCHEMBL6500578 0.83 HDAC7 (0.51) NPC1RAB9AHDAC7DHODHPRKAB2
SCHEMBL5535848 0.82 SLC6A3 (0.65) NPC1RAB9AHDAC7TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
US-20040157866-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157866-A1 Amide compounds APOB, NR1H2, NR1H3 NPC1 40/4885RAB9A 4004/4885HDAC7 975/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 NPC1 100/4885RAB9A 4382/4885HDAC7 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.